Response to “Optimizing palliative radiation: Beyond dose escalation in advanced head and neck squamous cell carcinoma”
- 29 November 2024
- journal article
- letter
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 202, 110656
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) – A phase 3 randomized controlled trialRadiotherapy and Oncology, 2024
- Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized StudyJournal of Clinical Oncology, 2023
- Cisplatin, Cetuximab, and Radiation in Locally Advanced Head and Neck Squamous Cell Cancer: A Retrospective ReviewClinical Medicine Insights: Oncology, 2015
- Association between severe treatment‐related lymphopenia and progression‐free survival in patients with newly diagnosed squamous cell head and neck cancerHead & Neck, 2013
- Quad shot: A short but effective schedule for palliative radiation for head and neck carcinomaIndian Journal of Palliative Care, 2009
- Tumour–induced immune modulation of sentinel lymph nodesNature Reviews Immunology, 2006
- Short course palliative radiotherapy of 20Gy in 5 fractions for advanced and incurable head and neck cancer: AIIMS studyRadiotherapy and Oncology, 2004